Format

Send to

Choose Destination
Trends Mol Med. 2014 Mar;20(3):137-42. doi: 10.1016/j.molmed.2013.12.004. Epub 2014 Jan 31.

Treating the whole not the hole: necessary coupling of technologies for diabetic foot ulcer treatment.

Author information

1
Stem Cell Therapies Laboratory, Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology at the Translational Research Institute, Brisbane, Australia.
2
Stem Cell Therapies Laboratory, Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology at the Translational Research Institute, Brisbane, Australia; Australian Prostate Cancer Research Centre-Queensland, Princess Alexandra Hospital, Brisbane, Australia; Mater Medical Research Institute at the Translational Research Institute, Brisbane, Australia. Electronic address: michael.doran@qut.edu.au.

Abstract

Type 2 diabetes is the epidemic of our generation, and diabetic foot ulcers (DFUs) are a major complication. Although DFU formation itself can indicate disease progression, the failure to effectively treat ulcers contributes further to a decay in patient quality of life and increased mortality. Herein we discuss the development of next-generation DFU therapies including: (i) topical growth factors, (ii) scaffolds, and (iii) cellular therapies. Individually these therapies have yielded measurable but modest improvements in DFU repair. Because DFUs arise as a result of multiple biochemical deficiencies, a singular treatment modality is unlikely to be effective. Next-generation DFU technologies must be combined to address effectively the complex underlying pathology and enable reliable DFU repair.

KEYWORDS:

diabetes; diabetic foot ulcers; growth factors; mesenchymal stem/stromal cells; scaffolds

PMID:
24485902
DOI:
10.1016/j.molmed.2013.12.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center